Department of Surgery, National Cancer Institute, Milan, Italy.
Ann Surg Oncol. 2010 Jan;17(1):45-53. doi: 10.1245/s10434-009-0756-2. Epub 2009 Oct 24.
Improved survival has been reported for diffuse malignant peritoneal mesothelioma (DMPM) treated by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). The significance of lymph node involvement in this disease is still poorly understood.
Prospectively collected clinical data on 83 consecutive patients with DMPM undergoing surgical cytoreduction and closed-abdomen HIPEC with cisplatin and doxorubicin were reviewed. Clinically suspicious lymph nodes were submitted to pathological examination. The impact of nodal involvement on survival was assessed by multivariate analysis; 14 clinicopathological control variables were tested.
For the overall series, median follow-up was 52 months (range 1-126 months) and 5-year overall survival (OS) was 49.5%. Lymph nodes were submitted to pathological examination in 38 patients, being positive in 11 and negative in 27. Lymph nodes were not clinically suspicious and not sampled in 45 patients. Iliac (n = 7) and paracolic (n = 2) nodes were the most commonly involved nodes. OS was 18.0% for patients with pathologically positive nodes and 82.5% for those with pathologically negative nodes (P = 0.0024). On multivariate analysis, pathologically negative (versus positive/not assessed) nodes [hazard ratio (HR) = 2.81; 95% confidence interval (CI) = 1.12-7.05; P = 0.027], epithelial subtype (HR = 2.93; CI = 1.24-6.95; P = 0.015), mitotic count <or=5/50 high-power microscopic fields (HPF) (HR = 5.34; CI = 1.96-14.54; P = 0.001), and completeness of cytoreduction (HR = 2.06; CI = 1.19-3.56; P = 0.001) correlated with increased OS. Positive nodes (versus negative/not assessed) did not significantly correlate with survival.
Pathologically negative nodes (as compared with pathological positive and not assessed), along with pathological and biological features, independently correlated with increased survival following comprehensive treatment. This suggests the need for careful node sampling when performing surgical cytoreduction for DMPM patients.
手术减瘤和腹腔内热灌注化疗(HIPEC)治疗弥漫性恶性腹膜间皮瘤(DMPM)已报道生存改善。淋巴结受累在这种疾病中的意义仍知之甚少。
对 83 例连续接受手术减瘤和顺铂和多柔比星闭合腹腔 HIPEC 治疗的 DMPM 患者的前瞻性临床数据进行了回顾性分析。对临床可疑淋巴结进行病理检查。通过多变量分析评估淋巴结受累对生存的影响;测试了 14 个临床病理对照变量。
对于整个系列,中位随访时间为 52 个月(范围 1-126 个月),5 年总生存率(OS)为 49.5%。38 例患者的淋巴结进行了病理检查,11 例阳性,27 例阴性。45 例患者的淋巴结无临床可疑且未取样。髂(n=7)和结肠旁(n=2)淋巴结是最常受累的淋巴结。病理阳性淋巴结患者的 OS 为 18.0%,病理阴性淋巴结患者的 OS 为 82.5%(P=0.0024)。多变量分析显示,病理阴性(与阳性/未评估)淋巴结[风险比(HR)=2.81;95%置信区间(CI)=1.12-7.05;P=0.027]、上皮亚型(HR=2.93;CI=1.24-6.95;P=0.015)、有丝分裂计数≤5/50 高倍镜视野(HPF)(HR=5.34;CI=1.96-14.54;P=0.001)和肿瘤细胞减灭术的完整性(HR=2.06;CI=1.19-3.56;P=0.001)与 OS 增加相关。阳性淋巴结(与阴性/未评估)与生存无显著相关性。
与病理阳性和未评估相比,病理阴性淋巴结(以及病理和生物学特征)与全面治疗后生存改善独立相关。这表明在为 DMPM 患者进行手术减瘤时需要仔细取样淋巴结。